Nanovision
Nanovision Biosciences Inc. is a preclinical UC San Diego spinoff developing an optoelectronic nanowire subretinal prosthesis intended to restore vision in patients with AMD and retinitis pigmentosa, with a secondary non-biological division applying the same nanowire imaging technology to low-light defense and commercial applications.
- Company typePrivate
- Founded2016
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Nanovision firmographics
Firmographics- Name
- Nanovision
- Legal name
- Nanovision Biosciences Inc.
- Website
- https://nanovisionbio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nanovision Biosciences Inc. is a preclinical UC San Diego spinoff developing an optoelectronic nanowire subretinal prosthesis intended to restore vision in patients with AMD and retinitis pigmentosa, with a secondary non-biological division applying the same nanowire imaging technology to low-light defense and commercial applications.
- Ownership category
- akta.pro rank
Nanovision industry classification
Industry- Product category
- Retinal Prosthesis / Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115), Research and Development in Nanotechnology (541713)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades) (HLAHAJAJ)
- akta.pro secondary industry
- Ophthalmic Regeneration (cornea/retina) (HLAAAGAK)
Keywords
Where Nanovision is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Nanovision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Implantable Medical Device Sales: As a preclinical medical device company developing a retinal prosthesis implant, Nanovision will generate revenue through the sale of its surgically implantable device to hospitals, eye clinics, and healthcare systems. Revenue model will likely be one-time device sales with associated professional services for implantation and follow-up care.
Go-to-market motion1 record
Marketing channels4 records
Nanovision product offering
Product offeringCore offering
Nanovision develops a surgically implantable subretinal retinal prosthesis based on optoelectronic nanowire technology. Arrays of light-sensitive silicon nanowires are bundled into small electrodes that convert incident light into electric fields stimulating inner retinal neurons, restoring vision in patients with photoreceptor death from degenerative retinal disorders such as AMD and retinitis pigmentosa. Integrated circuitry provides feedback control to modulate stimulus pulses and adapt to ambient light levels.
Product overview
Nanovision is developing a novel nanotechnology approach to retinal prosthesis with its core product: the Optoelectronic Nanowire Retinal Prosthesis. This device is an implantable subretinal implant that uses arrays of light-sensitive optoelectronic nanowires to convert incident light into electric fields that stimulate inner retinal neurons, restoring vision in patients with photoreceptor death. The company also operates a non-biological division applying its image sensor technology to low light imaging for defense and commercial applications.
Differentiator
Problem solved
Functional benefit
Brands
- Nanovision Labs: Working on future of core technologies for both biological and non-biological applications, pushing technical and engineering boundaries.
Quantifiable outcome
- Potentially achieves neural stimulation densities equivalent to biological resolution of photoreceptor neurons in the normal healthy eye
Companies that use Nanovision
Customer profileSegments2 records
Ideal customer profiles2 records
Nanovision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Nanovision partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- University of California, San Diego (UCSD)coreNanovision is a UC San Diego spinoff company. The partnership involves ongoing collaboration with UCSD's Jacobs Retina Center and the Shiley Eye Institute. Company founders include UCSD faculty members, and the technology was developed through research at the university. The Jacobs Retina Center is described as the only free-standing retina research center in the country.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Nanovision competitors and assessment
Company assessmentOthers
- Medtronic: Global medical device leader with deep experience in implantable neurostimulation devices. Relevant as a strategic acquirer / partner reference, with Nanovision board observer Paul Citron having spent 32 years at Medtronic.
- Clearside Biomedical: Specializes in suprachoroidal drug delivery for retinal diseases. Adjacent to Nanovision as another ophthalmic-focused innovator working on novel delivery approaches for retinal therapeutics, though focused on pharmacologics rather than electrical stimulation.
Emerging players
- LambdaVision: Develops an artificial retina using a light-activated protein-based approach rather than nanowires. Comparable as an emerging retinal prosthesis platform targeting similar end-stage RP/AMD indications, but with a fundamentally different biomaterial-based technology.
- Kodiak Sciences: Clinical-stage biopharma developing antibody-based therapeutics for retinal vascular diseases including AMD. Comparable as an emerging player targeting the same retinal disease patient population with a different (pharmaceutical) therapeutic modality.
Broad incumbents
- AbbVie (Allergan Aesthetics/eye care): Through its Allergan acquisition, AbbVie markets ophthalmic pharmaceuticals including treatments for retinal diseases. Comparable as an incumbent competing for the AMD/RP patient pool with pharmacologic rather than device-based therapies.
- Regeneron Pharmaceuticals: Markets Eylea, the leading anti-VEGF therapy for wet AMD and diabetic eye disease. Comparable as the dominant incumbent treatment provider for the same AMD patient population that Nanovision targets at the end-stage blindness indication.
- Genentech (Roche): Major biopharma company commercializing anti-VEGF therapies (Lucentis, Susvimo) for wet AMD. Comparable as an incumbent in the AMD treatment landscape whose drug therapies compete for the same patient population, even though the modality (pharmaceutical vs. implant) differs.
Direct peers
- Pixium Vision: French company developing the PRIMA photovoltaic subretinal prosthesis for AMD patients. Directly comparable as a subretinal implant using a different photo-stimulation architecture but targeting the same patient population and clinical use case.
- Second Sight Medical Products (now Cortigent): Developer of the Argus II retinal prosthesis, the most advanced commercially available retinal implant to date. Directly comparable as a retinal prosthesis company targeting AMD and RP patients with an implanted electrical stimulation device.
- Bionic Vision Technologies: Australian company developing a bionic eye / retinal prosthesis for retinitis pigmentosa. Directly comparable as a retinal implant company pursuing electrical stimulation of retinal neurons in patients with degenerative retinal disease.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Nanovision financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nanovision leadership team
Management profileNumber of profiles
Profiles8 records
Nanovision funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nanovision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nanovision
What does Nanovision do?
Nanovision develops a surgically implantable subretinal retinal prosthesis based on optoelectronic nanowire technology. Arrays of light-sensitive silicon nanowires are bundled into small electrodes that convert incident light into electric fields stimulating inner retinal neurons, restoring vision in patients with photoreceptor death from degenerative retinal disorders such as AMD and retinitis pigmentosa. Integrated circuitry provides feedback control to modulate stimulus pulses and adapt to ambient light levels.
Is Nanovision a public or private company?
Nanovision is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nanovision founded?
Nanovision was founded in 2016. It employs 11 to 50 people.
Where is Nanovision based?
Nanovision is headquartered in San Diego, United States, in the North America region.
How does Nanovision make money?
One revenue line is on record: implantable Medical Device Sales.
Who are Nanovision's main competitors?
Others on record are Medtronic and Clearside Biomedical. Emerging players are LambdaVision and Kodiak Sciences. Broad incumbents are AbbVie (Allergan Aesthetics/eye care), Regeneron Pharmaceuticals and Genentech (Roche). Direct peers are Pixium Vision, Second Sight Medical Products (now Cortigent) and Bionic Vision Technologies.
Does Nanovision have an API?
No public API is recorded for Nanovision.
What industry is Nanovision in?
Nanovision's product category is Retinal Prosthesis / Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAJ, Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades), with a secondary code of HLAAAGAK, Ophthalmic Regeneration (cornea/retina). Its NAICS code is 339115 and its SIC code is 3845.